Neogenomics price to free cash flow NEO

Market value divided by free cash flow over the last twelve months, since 2013.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 162×; Feb 2020
10-year median: 82.7×
10-year range: 34.8× to 393×
Peer median: 11.3×

Neogenomics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2020, at 162×.

On the days it had one over the last ten years, its median was 82.7×, from 34.8× in Mar 2017 to 393× in Sep 2017.

Price to free cash flow over time

median 82.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	162×	162×	195×
2019	170×	56.9×	203×
2018	55.1×	46.9×	190×
2017	303×	34.8×	393×
2016	37.4×	37.4×	168×
2015	188×	48.9×	196×
2014	52.8×	52.8×	239×
2013	200×	192×	210×

Against its peers

Companies in Specialty Business Services nearest Neogenomics' size, closest first, today.

Company	Price to free cash flow
NEONeogenomics	n/m
VVXV2X	17.8×
MHMcGraw Hill	8.3×
DFINDonnelley Financial Solutions	9.0×
CRAICRA International	n/m
ITGartner	11.3×
ULSUL Solutions	34.0×
Peer median	11.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Neogenomics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.